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Purpose: The purpose of this study was to compare leukemia-free survival (LFS) and other clinical
outcomes in patients with acute myelogenous leukemia who underwent a myeloablative allogeneic
stem cell transplant with and without total body irradiation (TBI).
Methods and materials: Adult patients with acute myelogenous leukemia undergoing
myeloablative allogeneic stem cell transplant at Duke University Medical Center between
1995 and 2012 were included. The primary endpoint was LFS. Secondary outcomes included
overall survival (OS), nonrelapse mortality, and the risk of pulmonary toxicity. Kaplan-Meier
survival estimates and Cox proportional hazards multivariate analyses were performed.
Results: A total of 206 patients were evaluated: 90 received TBI-based conditioning regimens
and 116 received chemotherapy alone. Median follow-up was 36 months. For all patients,
2-year LFS and OS were 36% (95% conﬁdence interval [CI], 29-43) and 39% (95% CI, 32-46),
respectively. After adjusting for known prognostic factors using a multivariate analysis, TBI
was associated with improved LFS (hazard ratio: 0.63; 95% CI: 0.44-0.91) and OS (hazard
ratio: 0.63; 95% CI, 0.43-0.91). There was no difference in nonrelapse mortality between
cohorts, but pulmonary toxicity was signiﬁcantly more common with TBI (2-year incidence
42% vs 12%, P < .001). High-grade pulmonary toxicity predominated with both conditioning
strategies (70% and 93% of cases were grade 3-5 with TBI and chemotherapy alone,
respectively).This study was presented at the 57th Annual Meeting of the American Society for Radiation Oncology, San Antonio, Texas, October 18-21, 2015.
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Nearly 4 decades ago, 2 groups independently reported
improved overall survival for patients with acute myeloge-
nous leukemia (AML) who underwent allogeneic stem cell
transplantation (allo-SCT) in ﬁrst complete remission after
being conditioned with cyclophosphamide and total body
irradiation (TBI).1,2 Myeloablative allo-SCT continues to
play a fundamental role in the management of AML. Allo-
SCT is generally recommended for patients with relapsed
disease and in appropriate patients in ﬁrst complete remis-
sion with intermediate- and high-risk disease based on
cytogenetics and/or molecular abnormalities.3
The optimal conditioning regimen preparatory to allo-
SCT is a subject of continued controversy. Whether TBI
is a critical component of the conditioning regimen, or if
chemotherapy-alone regimens are sufﬁcient, is a matter of
ongoing debate. This stems from conﬂicting results
between older randomized studies4-11 and more recent
retrospective analyses.12-16 Improvements in chemo-
therapy delivery, speciﬁcally the introduction of intrave-
nous busulfan,12 and technical challenges incorporating
TBI into a conditioning regimen, have generally led to
decreased utilization of TBI.
Further studies comparing these 2 approaches are
needed; therefore, we sought to review our institutional
experience in which a consistent TBI-based approach has
been used for many years. We also sought to examine
known prognostic factors to appropriately compare these
2 conditioning strategies.
Methods
Patients
This Institutional Review Boardeapproved, retrospec-
tive analysis evaluated all adult patients (18 years of age)
withAMLundergoing allo-SCTatDukeUniversityMedical
Center between 1995 and 2012. Only patients undergoing a
myeloablative conditioning regimen were included. Patient-
and treatment-related characteristics, including the speciﬁc
conditioning regimen, were recorded. The choice of
conditioning regimen was made at the discretion of the
treating physicians. Refractory disease was deﬁned as>5%
blasts by morphology immediately before transplant.
Potential prognostic factors were identiﬁed through a
literature search. These included age at diagnosis,9,14,17,18sex, pretransplant performance status, acute graft versus
host disease (GVHD),8,9,14,17 year of transplant,14 disease
status before transplant,8,14 and National Comprehensive
Cancer Network (NCCN) disease risk category.18,19
These factors were collected for each patient where
available. Two factors of potential prognostic signiﬁ-
cance, including donor age9 and donor sex,14 were not
available for a sufﬁcient number of patients for formal
analyses.
A uniform TBI technique was used with patients
treated to 13.5 Gy in 1.5 Gy twice-daily fractions using a
dose-rate of 15 to 20 cGy/minute. Patients were posi-
tioned supine and treated with lateral ﬁelds using 4- to
6-MV photons. The lungs were attenuated in all patients
to a dose of 8 to 10 Gy using the arms and brass com-
pensators. The degree of lung attenuation was determined
individually for each patient based primarily on pre-
transplant pulmonary function tests and the presence of
prior pulmonary disease.
All patients received care in a high-efﬁciency partic-
ulate air-ﬁltered room. Tunneled central venous catheters
were placed before beginning the conditioning regimen.
Antibiotic prophylaxis was used per standard prophylaxis
guidelines and included ciproﬂoxacin 750 mg by mouth
twice daily and metronidazole 500 mg by mouth three
times daily. Antiviral therapy included acyclovir 400 mg
by mouth twice daily. From 1995 through February 2009,
our prescribed fungal prophylaxis was ﬂuconazole
400 mg by mouth daily. After February 2009, prophylaxis
was changed to voriconazole 200 mg by mouth twice
daily. With the ﬁrst neutropenic fever, all patients were
started on intravenous antibiotic coverage with vanco-
mycin and ceftazidime. Sinusoid obstructive syndrome
prophylaxis was prescribed for all patients. From 1995
through June 2009, this was accomplished with low-dose
continuous heparin infusion until time of engraftment.
After June 2009, patients received ursodeoxycholic acid
orally until day 90 following transplant.
T-cell depletion in select patients was accomplished
with antithymocyte globulin, monoclonal anti-CD52 anti-
body-mediated depletion, or CD34 selection. Successful
engraftment was deﬁned as platelets >100  109/L,
neutrophils >1  109/L, and transfusion independence.
Statistical methods
Patient characteristics were summarized with median
(interquartile range) values for continuous variables and
Table 1 Patient characteristics
Characteristic All patients
(n Z 206)
Treatment group: n (%) P valuea
TBI þ chemotherapy
(n Z 90)
Chemotherapy
alone (n Z 116)
Age: median (IQR) 43 (33-50) 41 (31-49) 44 (36-50) .06
Sex
Female 94 (46) 38 (42) 56 (48) .39
Male 112 (54) 52 (58) 60 (52)
Pretransplant disease status .007
CR1 70 (34) 24 (27) 46 (40)
CR2-3 80 (39) 46 (51) 34 (29)
Refractory 55 (27) 20 (22) 35 (30)
Unavailable 1 (1) 0 (0) 1 (1)
NCCN risk group .40
Low 18 (9) 8 (9) 10 (9)
Intermediate 125 (61) 59 (66) 66 (57)
High 40 (19) 14 (16) 26 (22)
Unavailable 23 (11) 9 (10) 14 (12)
Preexisting MDS/MPD .62
Yes 31 (15) 12 (13) 19 (16)
No 175 (85) 78 (87) 97 (84)
Baseline pulmonary disease .54
Yes 46 (22) 22 (24) 24 (21)
No 160 (78) 68 (76) 92 (79)
KPS: median (IQR) 90 (80-90) 90 (80-90) 90 (80-90) .53
CMV baseline (patient) .80
Positive 116 (56) 50 (56) 66 (57)
Negative 68 (33) 28 (31) 40 (34)
Unavailable 22 (11) 12 (13) 10 (9)
CMV, cytomegalovirus; CR, complete response; IQR, interquartile range; KPS, Karnofsky performance status; MDS, myelodysplastic syndrome;
MPD, myeloproliferative disorder; NCCN, National Comprehensive Cancer Network; TBI, total body irradiation.
a Wilcoxon rank sum test for continuous variables and c2 test for categorical variables.
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by treatment group. The predeﬁned primary outcome of
interest was leukemia-free survival, deﬁned as date of
transplant to date of relapse or death from any
cause, with patients censored at date of last follow-up.
Secondary endpoints included overall survival, non-
relapse mortality, and the risk of pulmonary toxicity.20,21
Overall survival was deﬁned as date of transplant to
death from any cause, again with patients censored at
last follow-up. Nonrelapse mortality was deﬁned as date
of transplant to death not from relapse, with relapse as
the competing risk. The cumulative risk of pulmonary
toxicity was deﬁned as time from date of transplant to
date of any grade pulmonary toxicity, with death as the
competing risk. Pulmonary toxicity was scored using the
Common Terminology Criteria for Adverse Events,
version 4.0.
The Kaplan-Meier method was used to estimate
leukemia-free survival and overall survival, for all
patients and by treatment group. Six-, 12-, 18-, and
24-month rates were estimated with 95% conﬁdence in-
tervals (CIs) for both endpoints. The log-rank test was
used to compare outcomes between treatment groups.A Cox proportional hazards model was used to esti-
mate hazard ratios (HR) by treatment group after
adjustment for known and available covariates. Only
covariates that were signiﬁcant with a P value of .2 on
univariate analysis were included in the multivariate
model. Factors not signiﬁcant (P > .2) on univariate
analysis, and not included in the multivariate model,
were age, sex, pretransplant FEV1/DLCO, history of
tobacco abuse, T-cell depletion, preexisting myelodys-
plastic or myeloproliferative conditions, cytomegalovirus
reactivation, stem cell source (cord blood vs peripheral
blood), and pretransplant pulmonary disease. There were
24 patients with missing data for NCCN risk group.
NCCN risk group was associated with overall survival
and leukemia-free survival on univariate modeling
(P < .2) but not multivariate modeling, with the analysis
restricted to 182 patients with complete information;
therefore, this factor was not included in the ﬁnal anal-
ysis. One further patient was excluded from the covariate
analysis because of missing values.
HRs with 95% CIs were estimated for nonrelapse
mortality and the cumulative risk of pulmonary toxicity
with a proportional hazards model that accounted for
Table 2 Treatment characteristics
Characteristic All patients (n Z 206) Treatment group: n (%) P valuea
TBI þ chemotherapy
(n Z 90)
Chemotherapy
alone (n Z 116)
TBI-based regimen
Cyclophosphamide 32 (16) 32 (36)
Melphalan 13 (6) 13 (14)
Etoposide 2 (1) 2 (2)
Fludarabine 29 (14) 29 (32)
Other/unavailable 14 (7) 14 (16)
Chemotherapy-alone regimen
Busulfan/cyclophosphamide 81 (39) 81 (70)
Busulfan/ﬂudarabine 26 (13) 26 (22)
Busulfan/melphalan 9 (4) 9 (8)
Transplant type .004
Matched related donor 87 (42) 27 (30) 60 (52)
Matched unrelated donor 113 (55) 59 (66) 54 (47)
Other/unavailable 6 (3) 4 (4) 2 (2)
Donor source <.001
Cord blood 63 (31) 48 (53) 15 (13)
Bone marrow 1 (1) 1 (1) 0 (0)
Peripheral blood 137 (66) 41 (46) 96 (83)
Unavailable 5 (2) 0 (0) 5 (4)
T-cell depletion <.001
Yes 75 (36) 18 (20) 57 (49)
Antithymocyte globulin 25 (12) 7 (8) 18 (16)
CD34 selection 45 (22) 9 (10) 36 (31)
Anti-CD52 antibody 3 (1) 0 (0) 3 (3)
Method unavailable 2 (1) 2 (2) 0 (0)
No 125 (61) 67 (74) 58 (50)
Unavailable 6 (3) 5 (6) 1 (1)
CMV baseline (donor) .60
Positive 61 (30) 26 (29) 35 (30)
Negative 96 (47) 45 (50) 51 (44)
Unknown 49 (23) 11 (21) 30 (26)
Successful engraftment .18
Yes 179 (87) 75 (83) 104 (90)
Nob 27 (13) 15 (17) 12 (10)
Days to engraftment .26
Median (IQR) 30 (21-39) 30 (23-42) 30 (20-36)
CMV reactivation .09
Yes 76 (37) 39 (43) 37 (32)
No 130 (63) 51 (57) 84 (68)
Acute GVHD .09
Grade 0-1 128 (62) 50 (56) 78 (67)
Grade 2-4 78 (38) 40 (44) 38 (33)
GVHD, graft versus host disease. Other abbreviations as in Table 1.
a Wilcoxon rank sum test for continuous variables and c2 test for categorical variables.
b Includes patients who died before engraftment.
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Gray.22 Cumulative incidence functions were compared
between treatment groups, both univariately and after
adjustment for known covariates. All statistical analyses
were conducting using SAS, version 9.4 (SAS Institute,
Cary, NC).Results
Between 1995 and 2012, 206 patients underwent a
myeloablative allo-SCT for AML at our institution, 90
conditioned with a TBI-based regimen and 116 with
Figure 1 Kaplan-Meier of leukemia-free survival between
patients receiving total body irradiation (TBI) plus chemo-
therapy compared with chemotherapy alone.
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(44 months for the TBI cohort; 26 months for the
chemotherapy alone cohort). Patient characteristics are
summarized in Table 1. The most notable difference be-
tween the 2 groups was disease status before transplant.
Patients in ﬁrst complete remission were more likely to
have received chemotherapy alone regimens and patients
in second or third complete remission were more likely to
receive TBI-based regimens. Patients with refractory
disease who had not achieved complete remission before
initiating the conditioning regimen were more likely to
receive chemotherapy alone. Disease status at the time of
allo-SCT was ﬁrst complete remission in 34%, second
complete remission in 39%, with 27% having refractory
disease.
Preexisting pulmonary disease was present in 49 pa-
tients, including cryptogenic organizing pneumonia (nZ
1), bacterial pneumonia (n Z 23), aspergilloma (n Z 5),
asthma (n Z 12), acute respiratory distress syndrome
(n Z 1), drug-induced pulmonary toxicity (n Z 1),
diffuse alveolar hemorrhage (n Z 1), chronic obstructive
pulmonary disease (nZ 1), and unknown/other (nZ 4).
Treatment programs
Many patients underwent induction chemotherapy at
outside institutions before being referred to Duke Uni-
versity Medical Center for consideration of transplant.
Several different induction regimens were used, most
commonly “7þ3” with cytarabine plus idarubicin or
another anthracycline. The median number of induction
and consolidation cycles was both 2 and similar between
the 2 groups.All patients conditioned with chemotherapy alone
received busulfan as part of the preparative regimen, the
majority with a busulfan/cyclophosphamide regimen
(70%). The proportion receiving intravenous versus oral
busulfan was 56% and 44%, respectively. There was more
variation in chemotherapy agents combined with TBI but
the most common combination was TBI/cyclophospha-
mide (36%). Other agents used with TBI included
melphalan, etoposide, and ﬂudarabine. There was a
greater propensity of cord blood (53% vs 13%, P < .001)
and matched unrelated donor transplants (66% vs 47%, P
Z .004) in the TBI cohort. The overall engraftment rate
was 87%. The time to engraftment was the same between
treatment groups. Treatment characteristics can be found
in Table 2.
Clinical outcomes
The predeﬁned primary endpoint of the study was
leukemia-free survival. For all patients, the median
leukemia-free survival was 8 months with a 2-year
leukemia-free survival of 36% (95% conﬁdence interval
[CI], 29-43). Two-year leukemia-free survival was 43%
for TBI and 30% for chemotherapy alone (log-rank P Z
.12) (Fig 1). Factors associated with improved leukemia-
free survival on multivariate analysis included complete
remission status before transplant, successful engraftment,
more recent year of transplant, and receiving a TBI-based
regimen. Compared with chemotherapy-alone regimens,
the addition of TBI was associated with a HR of 0.63
(95% CI, 0.44-0.91; P Z .01) (Table 3).
The median overall survival for all patients was 13
months with a 2-year overall survival of 39% (95% CI,
32-46). Two-year overall survival was 45% for TBI-based
regimens compared with 34% for chemotherapy alone
(log-rank P Z .08) (Fig 2). Factors associated with
improved overall survival on multivariate analysis
included successful engraftment, more recent year of
transplant, and receiving TBI. Compared with chemo-
therapy alone, the HR for overall survival for TBI-based
regimens was 0.63 (95% CI, 0.43-0.91; P Z .02)
(Table 3).
Complications
Nonrelapse mortality did not differ between cohorts
with 2-year rates of 29% with TBI and 31% with
chemotherapy alone (P Z .83) (Fig 3). However, pul-
monary toxicity was signiﬁcantly more common in pa-
tients receiving TBI. The cumulative incidence of
pulmonary toxicity at 2 years was 42% with TBI
compared with 12% with chemotherapy alone (P < .001)
(Fig 4). High-grade pulmonary toxicity predominated
with both conditioning strategies (70% and 93% of cases
were grade 3-5 with TBI and chemotherapy alone,
Table 3 Proportional hazards multivariate model (N Z 205)
Variable Leukemia-free survival Overall survival Pulmonary toxicity
Hazard ratio (95% conﬁdence interval)
Karnofsky performance status 0.98 (0.96-1.00) 0.98 (0.96-1.01) 0.96 (0.93-0.99)
Pretransplant disease status
CR1 0.63 (0.40-0.98) 0.72 (0.46-1.14) 0.75 (0.38-1.48)
CR2-3 0.51 (0.33-0.79) 0.55 (0.35-0.87) 0.57 (0.27-1.22)
Refractory Reference Reference Reference
Acute GVHD 1.16 (0.80-1.69) 1.27 (0.86-1.85) 0.89 (0.51-1.54)
Successful engraftment 0.17 (0.10-0.27) 0.16 (0.10-0.27) 0.38 (0.20-0.75)
Year of transplant 0.91 (0.87-0.95) 0.91 (0.87-0.95) 0.97 (0.92-1.03)
Treatment group
Chemotherapy alone Reference Reference Reference
TBI þ chemotherapy 0.63 (0.44-0.91) 0.63 (0.43-0.91) 5.19 (2.65-10.15)
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improved performance status and successful engraftment
were associated with a decreased risk of pulmonary
toxicity. Alternatively, receiving TBI was associated with
an increased risk of posttransplant pulmonary toxicity.
Compared with chemotherapy alone, TBI-based regimens
had an HR of 5.19 (95% CI, 2.65-10.15; P < .001).
Acute grades 0-1 and 2-4 GVHD developed in 62%
and 38% of patients, respectively, and were not different
between cohorts. Lower grade acute GVHD (0-1) was
more common than higher grade GVHD (2-4) for both the
chemotherapy (67% and 33%, respectively) and chemo-
therapy plus TBI groups (56% and 44%, respectively).
Limited chronic GVHD developing more than 1 yearFigure 2 Kaplan-Meier of overall survival between patients
receiving total body irradiation (TBI) plus chemotherapy
compared with chemotherapy alone.from transplant and limited to 1 organ system was more
common than extensive chronic GVHD (13% and 7%,
respectively).Discussion
In this study, after correcting for known and available
prognostic factors, leukemia-free survival and overall
survival were improved when TBI was included in the
conditioning regimen before myeloablative allo-SCT for
AML. There are several reasons why a TBI-based con-
ditioning regimen might be advantageous. It provides a
noncross-resistant modality that complementsFigure 3 Cumulative incidence of nonrelapse mortality be-
tween patients receiving total body irradiation (TBI) plus
chemotherapy compared with chemotherapy alone.
Figure 4 Cumulative incidence of pulmonary toxicity (grades
1-5) between patients receiving total body irradiation (TBI) plus
chemotherapy compared with chemotherapy alone.
Table 4 Pulmonary toxicity
Type of toxicity Conditioning regimen
TBI þ
chemotherapy
(n Z 40)
Chemotherapy
alone (nZ 14)
Infectious 4 1
Diffuse alveolar
hemorrhage
7 4
Pulmonary edema 3 0
Pneumonitis 1 0
Radiographic changes
only
3 0
Multifactorial 9 2
Pulmonary toxicity
NOSa
13 7
Total 40 14
Grades 1-2 12 1
Grades 3-4 16 9
Grade 5b 12 4
Total 40 14
NOS, not otherwise speciﬁed.
a Underlying etiology unclear.
b Grade 5 indicates death from respiratory failure.
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successful strategy across numerous oncologic disease
sites. Further, there are no issues with blood supply and
metabolism/excretion issues are avoided. Finally,
although not as important with AML compared with acute
lymphoblastic leukemia, TBI treats sanctuary sites within
the central nervous system and testicles.
Historically, TBI was a standard component of AML
conditioning regimens. Chemotherapy alone strategies,
most commonly busulfan plus cyclophosphamide, were
introduced in the 1980s in an attempt to reduce transplant-
related morbidity, particularly radiation pneumonitis, and
also increase the likelihood of long-term remission.11
These regimens also expanded the availability of trans-
plant in centers with limited or no access to TBI. Potential
drawbacks to the traditional busulfan plus cyclophos-
phamide regimen include poor tolerability and unpre-
dictable pharmacodynamics with the oral busulfan
formulations.23 The relatively recent development of
intravenous busulfan may serve to counteract some of
these issues.14
Despite several decades of experience with both ap-
proaches, the optimal conditioning regimen for AML is
uncertain with conﬂicting conclusions in the literature.
There are only a few randomized studies. Most are small
and underpowered and many enrolled patients with other
leukemia subtypes such as acute lymphoblastic leukemia
and chronic myelogenous leukemia. An analysis of long-
term follow-up of 4 randomized studies, only 2 of which
enrolled patients with AML,4,9 suggested that clinical
outcomes were improved when TBI was used in the
conditioning regimen.11 Ten-year differences in disease-
free survival (57% vs 47%, P Z .051) and overall sur-
vival (63% vs 51%, P Z .068) appeared to be clinically
relevant, though not statistically signiﬁcant.
In contrast, numerous comparisons using registry data
have shown no consistent differences between the 2 most
common conditioning regimens: TBI/cyclophosphamide
and busulfan/cylophosphamide.13-16 A recent analysis by
Copelan et al observed that regimens containing oral
busulfan appeared to be equivalent to TBI/cyclophos-
phamide in regards to overall and leukemia free sur-
vival12; however, they found regimens containing
intravenous busulfan to be superior to TBI/cyclophos-
phamide. Shi-Xia and colleagues conducted a meta-
analysis of 18 controlled trials, some randomized but
most not, and found that TBI was associated with
improved disease-free survival in AML but with a greater
risk of interstitial pneumonia.10
Given these inconsistencies in the literature, we sought
to explore our institutional experience. In addition to the
observation that TBI was associated with improved
leukemia-free and overall survival, one of the most
striking differences between the 2 regimens was the risk
of pulmonary toxicity. Patients receiving TBI-based reg-
imens were far more likely to develop pulmonary toxicity(2-year rates 42% vs 12%; HR, 5.19; P < .001). Although
increased rates of pulmonary toxicity with TBI, specif-
ically interstitial pneumonitis, have been observed in
some series,10,15 others have not noted a signiﬁcant dif-
ference.4,7,9,11 Notably, Ringden et al reported an
increased rate of obstructive bronchiolitis in patients
receiving chemotherapy regimens compared with TBI.8 In
our series, pretransplant Karnofsky performance status
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0.38) were also risk factors for pulmonary toxicity. We
have previously demonstrated that the number of prior
chemotherapy regimens20 and poor exercise tolerance24
may also affect the risk of pulmonary toxicity.
Pulmonary toxicity following both TBI-based and
chemotherapy-alone preparative regimens can include
infectious pneumonia, interstitial pneumonitis, acute res-
piratory distress syndrome, and diffuse alveolar hemor-
rhage. The severity of pulmonary toxicity varies widely
from asymptomatic radiographic changes to respiratory
failure requiring intubation and sometimes death. Addi-
tionally, it can be quite difﬁcult to differentiate between
these various etiologies in the clinical setting without
invasive interventions, which are often not pursued. The
primary method to reduce the risk of pulmonary toxicity
in patients receiving TBI is lung shielding. We have
previously evaluated the use of cardiopulmonary exercise
testing to risk stratify patients prior to transplant.24 Given
high rates of severe pulmonary toxicity with TBI, further
strategies to mitigate this risk are clearly warranted.
Our study has several limitations. It is a retrospective
evaluation of a single center’s experience; thus, patient
selection and choice of conditioning regimen were not
controlled. Numerous conditioning regimens were used,
even between the 2 cohorts, making it difﬁcult to draw
ﬁrm conclusions about the efﬁcacy of a speciﬁc regimen.
Further, the graft source varied between TBI-based and
chemotherapy alone conditioning regimens, with cord
blood transplants conditioned primarily with TBI. How-
ever, most studies have shown comparable clinical out-
comes after allo-SCT for AML regardless of graft
source.25 Given the era studied, we did not have known
prognostic factors for all patients. This limited the breadth
of our multivariate analysis. Finally, only a minority of
patients received intravenous busulfan, which is now a
standard at our institution. The primary strength of our
study was the utilization of a uniform TBI protocol within
an experienced transplant center.Conclusion
In our experience, TBI-based regimens were associated
with superior leukemia-free and overall survival but at the
cost of increased pulmonary toxicity. Efforts and strate-
gies to reduce pulmonary toxicity are warranted.References
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